Business
Scancell Appoints Head of Business Development
Scancell Appoints Head of Business Development.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n7 September 2023\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nScancell Appoints Dr Mandeep Sehmi as Head of Business Development\nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the appointment of Dr Mandeep Sehmi as Head of Business Development, effective immediately.\n \nMandeep Sehmi brings more than 10 years of experience in business development and has previously held roles at leading UK biotech companies including at Abcam, where she managed and developed the cancer and metabolism portfolios, Cancer Research Technology, focussing on antibody out licensing, and Isogenica, where she was involved in deals for their antibody platform, including a multi-target deal with BioNTech. Mandeep joins Scancell from ImaginAb where she held the role of Director of Business Development and worked on a number of out-licensing opportunities for their lead asset with biotech and pharma in Immuno-oncology for cell therapies, vaccines and therapeutic antibodies. She holds a PhD in Cell and Molecular Biology and a Master's degree in Molecular Pathology and Toxicology from the University of Leicester, UK.\n \nProf Lindy Durrant, Chief Executive Officer of Scancell, commented: \"The appointment of Mandeep is an exciting development for Scancell as we continue to expand our commercial capabilities. As communicated at the time of the recent business update, our strategic focus is on the continued development of the Company's two lead clinical assets SCIB1 and Modi-1. The value of our antibody platform, however, remains a powerful asset in enabling us to generate revenue through high value licence agreements and Mandeep, with her extensive network and business development experience in the antibody sector, will be invaluable as the Company continues to pursue attractive commercialisation avenues for our therapeutic assets. We welcome Mandeep to the team and look forward to working with her as we strive to bring innovative medicines to patients while maximising value for our shareholders.\"\n \nDr Mandeep Sehmi, Head of Business Development at Scancell, added: \"Scancell's innovative cancer vaccines and antibodies have the potential to make a real difference in the treatment of cancer. The commercial licence a...